USANA Health Sciences, Inc. (NYSE: USNA) today announced financial results for its fiscal third quarter ended September 28, 2024.
Key Financial & Operating Results
Third quarter net sales were $200 million versus $213 million during Q3 2023.
Third quarter diluted EPS was $0.56 as compared with $0.59 during Q3 2023.
Company updates fiscal year 2024 net sales and diluted EPS outlook to approximately $850 million and $2.45, respectively (previously $850 million to $880 million and $2.40 to $2.55).
Q3 2024 Financial Performance
Consolidated Results
Net Sales
$200 million
-6% vs. Q3 2023
No meaningful YOY FX impact
-6% sequentially
Diluted EPS
$0.56
-5% vs. Q3 2023
+4% sequentially
Active Customers
452,000
-3% vs. Q3 2023
-3% sequentially
“Third quarter operating results reflected continued top line headwinds across many of our key markets,”
said Jim Brown, President and Chief Executive Officer.
“Our sales force continued to face challenges in attracting new customers as consumer sentiment remained cautious, including in our largest market, mainland China. Despite these challenges, we remain confident in our direction and continue to make progress on the five key initiatives that underpin our long-term strategy. Our commercial team, which was reorganized earlier this year, has been executing on these initiatives to enhance the overall value proposition of our business to our customers and we are beginning to see results